STARTUP PROFILE

Precision Neuroscience

COUNTRY

USA

FOUNDED

2016

CATEGORY

Brain-Computer Interface

Developing the Layer 7 Cortical Interface, a minimally invasive, high-resolution brain–computer implant to restore communication and independence via thought.

Visit website →

← Back to Startups

•

Neurofounders Insights

$ Funding -

Series C+

MODALITY

ECoG

FORM FACTOR

Implant

INTERFACE DEPTH

Implantable

INDICATION

Stroke

TARGET USER

Patients

REGULATORY STAGE

Investigational

Precision Neuroscience is differentiated by its thin, minimally invasive Layer 7 cortical implant designed to achieve high-resolution recording with less tissue disruption than penetrating arrays. It is one of the more credible near-term implantable BCI companies, positioned between invasive bandwidth and surgical practicality.

Related companies

•

Mentioned in Market Notes

MOST RECENT COVERAGE

No items found.

Articles featuring

Precision Neuroscience

BCI Enters a New Funding Stage

A 17-company BCI snapshot shows $1.75B raised in the last 12 months, exceeding prior cumulative funding for the same set. The gains remain concentrated among a small number of firms.

Five Ways to Read the Brain; Beyond EEGs

Brain interfaces rely on more than EEG. This piece maps five ways neural signals are accessed, from muscle activity to intracortical implants, and explains how trade-offs in fidelity, invasiveness, and usability shape real-world systems.

Precision Partners with Medtronic to Integrate Interfaces into Neurosurgery

Precision Neuroscience’s partnership with Medtronic embeds cortical interfaces into surgical navigation. The move highlights workflow integration as a pragmatic commercialization path for BCIs.

Ten BCI Companies Now in Human Trials

Brain-computer interfaces are entering regulated human trials across invasive, minimally invasive, and non-invasive approaches, signalling a shift from experimental demos to real clinical pipelines.

The Big 6 of BCI: Where Neurotech Funding Is Flowing

Capital is concentrating around six invasive BCI leaders as investors back platforms with repeatable surgery, stable signals, and clear regulatory paths. The field is shifting from proof-of-concept to execution.